By using this site, you agree to the Privacy Policy and Terms of Use.
Accept
SinfrasSinfras
Aa
  • Home
  • Diet
  • Gadgets
  • Sports
  • Education
  • Social Media
  • Clothing
  • News
  • Contact Us!
  • Privacy Policy
Reading: FDA panel votes to remove serious warning from Chantix label
Share
Aa
SinfrasSinfras
Search
  • Home
  • Diet
  • Gadgets
  • Sports
  • Education
  • Social Media
  • Clothing
  • News
  • Contact Us!
  • Privacy Policy
Have an existing account? Sign In
Follow US
© 2022 Foxiz News Network. Ruby Design Company. All Rights Reserved.
Sinfras > Diet > FDA panel votes to remove serious warning from Chantix label
Diet

FDA panel votes to remove serious warning from Chantix label

Saheli
Last updated: 2016/09/16 at 12:50 PM
By Saheli 4 Min Read
Share

Warnings that the smoking cessation drug Chantix can cause side effects such as suicidal thoughts and hostility may come off the drug’s label based on a new study suggesting the warning is unjustified.

An advisory panel at the U.S. Food and Drug Administration voted to recommend the agency remove the black box warning for the potential of Chantix to cause the side effects, according to the drug’s manufacturer, Pfizer.

Chantix has been available for about a decade, with concerns about the neuropsychological effects of the drug popping up almost instantly. Between the concerns about suicide and hostility in patients using the drug, and thousands of lawsuits from some who did take it, the drug has not become the runaway hit it was expected to be.

Pfizer has been working to have the label changed for at least two years but failed over questions with new research. An FDA panel raised questions about a new study,published in April in The Lancet, purporting to show the drug is safe and that patients using the drug did not experience psychological side effects significantly more often than those not on the drug while quitting smoking.

In the study, researchers recruited 8,144 participants between the ages of 18 and 75 who smoked more than 10 cigarettes per day and most of whom had tried to quit at least once before, treating them with either Chantix, the patch or placebo.

Of patients diagnosed with a psychiatric disorder, 6.5 percent of participants on Chantix experienced an adverse psychological effect, compared to 4.9 percent of those given a placebo. Of patients who had not been previously diagnosed with a psychiatric disorder, 1.3 percent of participants on Chantix experienced a side effect, compared to 2.4 percent of those given a placebo.

The vote to recommend changing the label was not unanimous — 10 members of the board voted to remove it, four voted to change it and five said it should not change — and almost immediately brought criticism, at least partially based on earlier questions about the study used to justify changing the label.

“A Black Box warning has been rescinded very few times in the past,” Sammy Almashat, a researcher associate at the healthcare advocacy group Public Citizen,told STAT. “This could set an ominous precedent. If the FDA rescinds, a company can now go to the agency with a substandard post-marketing trial, point to Chantix and demand the same outcome. We’re worried that if the FDA follows through with the recommendation, that this will become a new standard for removing a black box.”

The advisory board’s recommendation does not mean the FDA will necessarily remove the black box warning on Chantix, which will have to vote separately on whether to remove the warning or change the drug’s label at all.

Pfizer has proposed removing the black box warning, but updating the Chantix label to reflect to risk for psychological side effects based on the newer study, called EAGLES, which it thinks will sufficiently warn patients of their potential.

“We are pleased with the Committees’ recommendation to remove the boxed warning,” Dr. Freda Lewis-Hall, chief medical officer and executive vice president at Pfizer, said in a press release, “and believe this is an important step toward updating the Chantix labeling to more accurately reflect its neuropsychiatric safety profile and help patients and prescribers make informed decisions about treatment options.”

[Source:-UPI]

Share this:

  • Tweet
  • Share on Tumblr
  • WhatsApp
TAGGED: Chantix, FDA, From, label, panel, remove, serious, to, votes, warning
Saheli September 16, 2016
Previous Article New method allows ear tumor removal without removing piece of skull
Next Article Older adults benefit from laughter during exercise programs

Latest News

The Thermo Diet: Ignite Your Metabolism and Achieve Optimal Health
Diet
The Pegan Diet: A Comprehensive Guide in PDF Format for Optimal Health and Balanced Nutrition
Diet
Delicious and Nourishing Recipes for the Specific Carbohydrate Diet: Embrace Health with Flavorful SCD Meals
Diet
SIBO Prep Diet: A Comprehensive Guide to Managing Small Intestinal Bacterial Overgrowth
Diet

Most Viewed Posts

  • Online education must supplement, not replace, physical sites of learning
  • Choosing Nursing as a Second Career
  • Pegasus plus dietary supplement
  • Think about what your target audience would find helpful & engaging. Keep a list of your favorite sources so it’s quick & easy to find links when you do status updates.
Join Us!

Subscribe to our newsletter and never miss our latest news, podcasts etc..

[mc4wp_form]
Zero spam, Unsubscribe at any time.

Removed from reading list

Undo
Welcome Back!

Sign in to your account

Lost your password?